Title: A clinical study on the expression of E-cadherin and γ-catenin in human non-small cell lung cancer
Abstract: Objective:To investigate the role of E-cadherin(E-cad)and γ-catenin(γ-cat)in development and prognosis of non-small cell lung cancer(NSCLC).Methods:Forty-three specimens of resected,paraffin embedded NSCLC and 7 cases of normal lung tissues were examined by immunohistochemical technique for the expression of E-cad and γ-cat.Results:Of the 43 NSCLC cases,the abnormal rates of E-cad and γ-cat protein were 58.1% and 67.4% respectively,which were significantly higher than normal lung specimens(P0.05,P0.01).The abnormal expression of E-cad was significantly correlated with lymph node metastasis(P0.01)and TNM stage(P0.01).The abnormal expression of γ-cat was more frequently found in the adenocarcinomas than in the squamous cell carcinomas(P0.05)and was significantly correlated with lymph node metastasis(P0.05).The survival time was significantly shorter in patients with E-cad or γ-cat abnormal expression than in patients with E-cad or γ-cat normal expression(median,16 vs 35 months,P0.01;20 vs 32 months,P0.05).While using the proportional hazards regression model(Cox model),E-cad could serve as an independent prognosis factor.There was a positive relationship between the expression of E-cad and γ-cat(r=0.416,P=0.007).When E-cad and γ-cat were analyzed as one group,lymph node metastasis rate was lower(P0.01)and survival time was longer(median,45 vs 20 months,P0.01)in patients with E-cad and γ-cat normal expression than in patients with only one normal expression of these two proteins.Conclusion:E-cad and γ-cat play important roles in development and progression of NSCLC.E-cad and γ-cat may be useful to determine prognosis and clinical strategies.Moreover,when E-cad and γ-cat were examined together,the accuracy of predicting lymph node metastasis and prognosis of NSCLC could be increased.
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot